Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	transcription coactivator activity	MTA2 BCL9L KAT5 TRIM62 ZFPM2 ZXDB USP21	1.97e-04	303	79	7	GO:0003713
GeneOntologyMolecularFunction	guanyl-nucleotide exchange factor activity	GBF1 ARHGEF1 DENND4B NUCB1 ARHGEF11 FGD6	3.09e-04	231	79	6	GO:0005085
GeneOntologyCellularComponent	protein acetyltransferase complex	KANSL2 KAT5 KANSL1 NAA10	5.92e-04	104	77	4	GO:0031248
GeneOntologyCellularComponent	H4 histone acetyltransferase complex	KANSL2 KAT5 KANSL1	6.10e-04	45	77	3	GO:1902562
GeneOntologyCellularComponent	acetyltransferase complex	KANSL2 KAT5 KANSL1 NAA10	7.06e-04	109	77	4	GO:1902493
GeneOntologyCellularComponent	NSL complex	KANSL2 KANSL1	7.21e-04	11	77	2	GO:0044545
MousePheno	absent paraxial mesoderm	MESP2 MESP1 MSGN1	6.52e-06	9	61	3	MP:0012184
MousePheno	testis degeneration	CLCN2 USP42 IP6K1	5.15e-05	17	61	3	MP:0013600
MousePheno	abnormal motile cilium physiology	GAS8 DNAI2 ULK4 ODAD3	7.03e-05	51	61	4	MP:0013209
MousePheno	abnormal cilium physiology	GAS8 DNAI2 ULK4 ODAD3	8.19e-05	53	61	4	MP:0013208
Domain	RGS-like	ARHGEF1 ARHGEF11	4.89e-05	3	76	2	PF09128
Domain	RGS-like_dom	ARHGEF1 ARHGEF11	4.89e-05	3	76	2	IPR015212
Domain	USP_CS	CYLD USP34 USP42 USP21	1.51e-04	66	76	4	IPR018200
Domain	USP_1	CYLD USP34 USP42 USP21	1.89e-04	70	76	4	PS00972
Domain	UCH	CYLD USP34 USP42 USP21	2.00e-04	71	76	4	PF00443
Domain	USP_2	CYLD USP34 USP42 USP21	2.00e-04	71	76	4	PS00973
Domain	USP_3	CYLD USP34 USP42 USP21	2.11e-04	72	76	4	PS50235
Domain	USP_dom	CYLD USP34 USP42 USP21	2.11e-04	72	76	4	IPR028889
Domain	Peptidase_C19_UCH	CYLD USP34 USP42 USP21	2.11e-04	72	76	4	IPR001394
Domain	-	MXD3 MESP2 MESP1 MSGN1	1.02e-03	109	76	4	4.10.280.10
Domain	HLH	MXD3 MESP2 MESP1 MSGN1	1.09e-03	111	76	4	PF00010
Domain	HLH	MXD3 MESP2 MESP1 MSGN1	1.28e-03	116	76	4	SM00353
Domain	BHLH	MXD3 MESP2 MESP1 MSGN1	1.33e-03	117	76	4	PS50888
Domain	bHLH_dom	MXD3 MESP2 MESP1 MSGN1	1.37e-03	118	76	4	IPR011598
Domain	RhoGEF	ARHGEF1 ARHGEF11 FGD6	2.68e-03	68	76	3	SM00325
Domain	RhoGEF	ARHGEF1 ARHGEF11 FGD6	2.91e-03	70	76	3	PF00621
Domain	DH_2	ARHGEF1 ARHGEF11 FGD6	2.91e-03	70	76	3	PS50010
Domain	DH-domain	ARHGEF1 ARHGEF11 FGD6	3.03e-03	71	76	3	IPR000219
Domain	-	ARHGEF1 ARHGEF11 FGD6	3.03e-03	71	76	3	1.20.900.10
Domain	Pentatricopeptide_repeat	ASZ1 DENND4B	3.91e-03	23	76	2	IPR002885
Domain	Znf_RING_CS	RC3H1 TRIM62 ARIH2 TRIM3	4.41e-03	163	76	4	IPR017907
Domain	Znf-RING_LisH	RC3H1 TRIM3	8.43e-03	34	76	2	IPR027370
Domain	zf-RING_UBOX	RC3H1 TRIM3	8.43e-03	34	76	2	PF13445
Pathway	REACTOME_ABORTIVE_ELONGATION_OF_HIV_1_TRANSCRIPT_IN_THE_ABSENCE_OF_TAT	POLR2A CTDP1 POLR2L	8.91e-05	23	54	3	M3630
Pathway	REACTOME_PIWI_INTERACTING_RNA_PIRNA_BIOGENESIS	ASZ1 POLR2A POLR2L	1.81e-04	29	54	3	M27462
Pathway	REACTOME_HIV_ELONGATION_ARREST_AND_RECOVERY	POLR2A CTDP1 POLR2L	2.67e-04	33	54	3	M27010
Pathway	REACTOME_FORMATION_OF_THE_EARLY_ELONGATION_COMPLEX	POLR2A CTDP1 POLR2L	2.67e-04	33	54	3	MM14508
Pathway	REACTOME_FORMATION_OF_THE_EARLY_ELONGATION_COMPLEX	POLR2A CTDP1 POLR2L	2.67e-04	33	54	3	M26919
Pathway	REACTOME_DEATH_RECEPTOR_SIGNALING	CYLD ARHGEF1 AATF ARHGEF11 USP21	3.00e-04	154	54	5	M27697
Pubmed	The bHLH class protein pMesogenin1 can specify paraxial mesoderm phenotypes.	MESP2 MESP1 MSGN1	4.35e-06	14	81	3	10837126
Pubmed	Prediction of the coding sequences of unidentified human genes. IX. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro.	USP34 TBC1D4 SFI1 SMC5 OPA1	4.86e-06	105	81	5	9628581
Pubmed	Repurposing of the enhancer-promoter communication underlies the compensation of Mesp2 by Mesp1.	MESP2 MESP1	5.36e-06	2	81	2	35025872
Pubmed	Arhgef1 Plays a Vital Role in Platelet Function and Thrombogenesis.	ARHGEF1 ARHGEF11	5.36e-06	2	81	2	30994039
Pubmed	Transcriptional regulation of Mesp1 and Mesp2 genes: differential usage of enhancers during development.	MESP2 MESP1	5.36e-06	2	81	2	11578861
Pubmed	The roles of Mesp family proteins: functional diversity and redundancy in differentiation of pluripotent stem cells and mammalian mesodermal development.	MESP2 MESP1	5.36e-06	2	81	2	26088191
Pubmed	Identification of presomitic mesoderm (PSM)-specific Mesp1 enhancer and generation of a PSM-specific Mesp1/Mesp2-null mouse using BAC-based rescue technology.	MESP2 MESP1	5.36e-06	2	81	2	18328678
Pubmed	Rho GEF Lsc is required for normal polarization, migration, and adhesion of formyl-peptide-stimulated neutrophils.	ARHGEF1 ARHGEF11	5.36e-06	2	81	2	16263795
Pubmed	Regulated localization is sufficient for hormonal control of regulator of G protein signaling homology Rho guanine nucleotide exchange factors (RH-RhoGEFs).	ARHGEF1 ARHGEF11	5.36e-06	2	81	2	24855647
Pubmed	An siRNA library screen identifies CYLD and USP34 as deubiquitinases that regulate GPCR-p38 MAPK signaling and distinct inflammatory responses.	CYLD USP34	5.36e-06	2	81	2	37865315
Pubmed	Hedgehog-FGF signaling axis patterns anterior mesoderm during gastrulation.	MESP2 MESP1 MSGN1	5.43e-06	15	81	3	32561646
Pubmed	The murine winged helix transcription factors, Foxc1 and Foxc2, are both required for cardiovascular development and somitogenesis.	MESP2 MESP1 MSGN1	1.15e-05	19	81	3	11562355
Pubmed	Construction of expression-ready cDNA clones for KIAA genes: manual curation of 330 KIAA cDNA clones.	CYLD USP34 GBF1 APAF1 CDC5L SMC5	1.49e-05	225	81	6	12168954
Pubmed	Cooperative Mesp activity is required for normal somitogenesis along the anterior-posterior axis.	MESP2 MESP1	1.60e-05	3	81	2	16996494
Pubmed	Thrombin and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate cancer cells.	ARHGEF1 ARHGEF11	1.60e-05	3	81	2	15143072
Pubmed	Human phosphorylated CTD-interacting protein, PCIF1, negatively modulates gene expression by RNA polymerase II.	POLR2A CTDP1	1.60e-05	3	81	2	18294453
Pubmed	Mechanistic insights into specificity, activity, and regulatory elements of the regulator of G-protein signaling (RGS)-containing Rho-specific guanine nucleotide exchange factors (GEFs) p115, PDZ-RhoGEF (PRG), and leukemia-associated RhoGEF (LARG).	ARHGEF1 ARHGEF11	1.60e-05	3	81	2	21454492
Pubmed	B plexins activate Rho through PDZ-RhoGEF.	ARHGEF1 ARHGEF11	1.60e-05	3	81	2	12372594
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	CYLD CDK17 AMPD2 GBF1 TBC1D4 ERCC6L ARHGEF1 NAA10 LAMC1 FGD6	3.15e-05	861	81	10	36931259
Pubmed	COX17 acetylation via MOF-KANSL complex promotes mitochondrial integrity and function.	KANSL2 KANSL1	3.20e-05	4	81	2	37813994
Pubmed	Males absent on the first (MOF): from flies to humans.	KANSL2 KANSL1	3.20e-05	4	81	2	17694080
Pubmed	Pro-prion, as a membrane adaptor protein for E3 ligase c-Cbl, facilitates the ubiquitination of IGF-1R, promoting melanoma metastasis.	GBF1 SYNE3 USP42 ERCC6L SLC4A1AP DENND4B SCAPER LAMC1 FGD6	3.27e-05	689	81	9	36543142
Pubmed	Protein interactome reveals converging molecular pathways among autism disorders.	KANSL2 NUCB1 LAMC1 AATF CCDC88B TRIM3 ZFPM2 RIC3	4.93e-05	560	81	8	21653829
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	MTA2 USP34 GBF1 SYNE3 MAN2B1 KANSL1 POLR2A CTDP1 ULK4 SFI1 ARHGEF11	5.03e-05	1105	81	11	35748872
Pubmed	The FCP1 phosphatase interacts with RNA polymerase II and with MEP50 a component of the methylosome complex involved in the assembly of snRNP.	POLR2A CTDP1	5.33e-05	5	81	2	12560496
Pubmed	Functional importance of evolutionally conserved Tbx6 binding sites in the presomitic mesoderm-specific enhancer of Mesp2.	MESP2 MESP1	5.33e-05	5	81	2	18849530
Pubmed	Differential contributions of Mesp1 and Mesp2 to the epithelialization and rostro-caudal patterning of somites.	MESP2 MESP1	5.33e-05	5	81	2	15677726
Pubmed	OTUD6A Is an Aurora Kinase A-Specific Deubiquitinase.	CYLD USP42 USP21	5.75e-05	32	81	3	33669244
Pubmed	The RNA polymerase II elongation complex.	POLR2A CTDP1 POLR2L	6.31e-05	33	81	3	12676794
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	KANSL2 GBF1 TBC1D4 KANSL1 USP42 ERCC6L SLC4A1AP POLR2A CTDP1	7.99e-05	774	81	9	15302935
Pubmed	The RNA polymerase II C-terminal domain promotes splicing activation through recruitment of a U2AF65-Prp19 complex.	POLR2A CDC5L	7.99e-05	6	81	2	21536736
Pubmed	The BRCT domain is a phospho-protein binding domain.	POLR2A CTDP1	7.99e-05	6	81	2	14576433
Pubmed	Potent activation of RhoA by Galpha q and Gq-coupled receptors.	ARHGEF1 ARHGEF11	7.99e-05	6	81	2	12016230
Pubmed	A bacterial effector targets host DH-PH domain RhoGEFs and antagonizes macrophage phagocytosis.	ARHGEF1 ARHGEF11	7.99e-05	6	81	2	20300064
Pubmed	Nuclear pore components are involved in the transcriptional regulation of dosage compensation in Drosophila.	KANSL2 KANSL1	1.12e-04	7	81	2	16543150
Pubmed	Mesp2 and Tbx6 cooperatively create periodic patterns coupled with the clock machinery during mouse somitogenesis.	MESP2 MSGN1	1.12e-04	7	81	2	18579680
Pubmed	The extracellular domain of Lrp5/6 inhibits noncanonical Wnt signaling in vivo.	MESP2 MSGN1	1.12e-04	7	81	2	19056682
Pubmed	The tumour suppressor CYLD regulates the p53 DNA damage response.	CYLD USP21	1.12e-04	7	81	2	27561390
Pubmed	KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.	MTA2 SLC12A6 CDK17 ARHGEF1 SCAPER CTNNA2 SPECC1L CDC5L ARHGEF11 CCDC177 OPA1 TRIM3	1.15e-04	1431	81	12	37142655
Pubmed	A protein phosphatase from human T cells augments tat transactivation of the human immunodeficiency virus type 1 long-terminal repeat.	POLR2A CTDP1	1.49e-04	8	81	2	12036313
Pubmed	FCP1, the RAP74-interacting subunit of a human protein phosphatase that dephosphorylates the carboxyl-terminal domain of RNA polymerase IIO.	POLR2A CTDP1	1.49e-04	8	81	2	9765293
Pubmed	Disruption of KCC2 reveals an essential role of K-Cl cotransport already in early synaptic inhibition.	SLC12A6 CLCN2	1.49e-04	8	81	2	11395011
Pubmed	The zinc finger and C-terminal domains of MTA proteins are required for FOG-2-mediated transcriptional repression via the NuRD complex.	MTA2 ZFPM2	1.49e-04	8	81	2	18067919
Pubmed	Live imaging of heart tube development in mouse reveals alternating phases of cardiac differentiation and morphogenesis.	POLR2A MESP1	1.91e-04	9	81	2	29202929
Pubmed	The repression of Notch signaling occurs via the destabilization of mastermind-like 1 by Mesp2 and is essential for somitogenesis.	MESP2 MESP1	1.91e-04	9	81	2	21098559
Pubmed	MKRN2 Physically Interacts with GLE1 to Regulate mRNA Export and Zebrafish Retinal Development.	RHOB RC3H1 POLR2A POLR2L CDC5L OPA1	1.93e-04	358	81	6	32460013
Pubmed	A novel RNA polymerase II C-terminal domain phosphatase that preferentially dephosphorylates serine 5.	POLR2A CTDP1	2.38e-04	10	81	2	12721286
Pubmed	Crosstalk between NSL histone acetyltransferase and MLL/SET complexes: NSL complex functions in promoting histone H3K4 di-methylation activity by MLL/SET complexes.	KANSL2 KANSL1	2.38e-04	10	81	2	24244196
Pubmed	Interactions between the full complement of human RNA polymerase II subunits.	POLR2A POLR2L	2.38e-04	10	81	2	10567706
Pubmed	Interactions between the human RNA polymerase II subunits.	POLR2A POLR2L	2.38e-04	10	81	2	9201987
Pubmed	The C-terminal domain phosphatase and transcription elongation activities of FCP1 are regulated by phosphorylation.	POLR2A CTDP1	2.38e-04	10	81	2	12591939
Pubmed	Dynamic expression and essential functions of Hes7 in somite segmentation.	MESP2 MSGN1	2.91e-04	11	81	2	11641270
Pubmed	Inositol hexakisphosphate kinase 3 promotes focal adhesion turnover via interactions with dynein intermediate chain 2.	DNAI2 IP6K1	2.91e-04	11	81	2	30718399
Pubmed	Neural metabolic imbalance induced by MOF dysfunction triggers pericyte activation and breakdown of vasculature.	KANSL2 KANSL1	2.91e-04	11	81	2	32541879
Pubmed	[Positive and negative regulation of transcription from HIV provirus].	POLR2A POLR2L	2.91e-04	11	81	2	21972559
Pubmed	Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein.	POLR2A POLR2L	2.91e-04	11	81	2	2190099
Pubmed	Mesp2: a novel mouse gene expressed in the presegmented mesoderm and essential for segmentation initiation.	MESP2 MESP1	2.91e-04	11	81	2	9242490
Pubmed	Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization.	CDK17 GBF1 TBC1D4 CDC5L FGD6	3.32e-04	255	81	5	15324660
Pubmed	The bHLH regulator pMesogenin1 is required for maturation and segmentation of paraxial mesoderm.	MESP2 MSGN1	3.48e-04	12	81	2	11124811
Pubmed	Promoter influences transcription elongation: TATA-box element mediates the assembly of processive transcription complexes responsive to cyclin-dependent kinase 9.	POLR2A POLR2L	3.48e-04	12	81	2	18218627
Pubmed	Human immunodeficiency virus type 1 Tat-dependent activation of an arrested RNA polymerase II elongation complex.	POLR2A POLR2L	3.48e-04	12	81	2	10069959
Pubmed	MesP1 is expressed in the heart precursor cells and required for the formation of a single heart tube.	MESP2 MESP1	3.48e-04	12	81	2	10393122
Pubmed	Trans-activation by human immunodeficiency virus Tat protein requires the C-terminal domain of RNA polymerase II.	POLR2A POLR2L	3.48e-04	12	81	2	8876177
Pubmed	Human immunodeficiency virus type-1 Tat is an integral component of the activated transcription-elongation complex.	POLR2A POLR2L	3.48e-04	12	81	2	8637904
Pubmed	Subunit composition and substrate specificity of a MOF-containing histone acetyltransferase distinct from the male-specific lethal (MSL) complex.	KANSL2 KANSL1	3.48e-04	12	81	2	20018852
Pubmed	RPAP1, a novel human RNA polymerase II-associated protein affinity purified with recombinant wild-type and mutated polymerase subunits.	POLR2A CTDP1	3.48e-04	12	81	2	15282305
Pubmed	A bimolecular mechanism of HIV-1 Tat protein interaction with RNA polymerase II transcription elongation complexes.	POLR2A POLR2L	3.48e-04	12	81	2	12126615
Pubmed	Requirements for RNA polymerase II carboxyl-terminal domain for activated transcription of human retroviruses human T-cell lymphotropic virus I and HIV-1.	POLR2A POLR2L	3.48e-04	12	81	2	8910388
Pubmed	Appropriate suppression of Notch signaling by Mesp factors is essential for stripe pattern formation leading to segment boundary formation.	MESP2 MESP1	3.48e-04	12	81	2	17306789
Pubmed	BRCA1 is a component of the RNA polymerase II holoenzyme.	POLR2A CTDP1	3.48e-04	12	81	2	9159119
Pubmed	High-throughput mapping of a dynamic signaling network in mammalian cells.	CDK17 ARHGEF1 ARHGEF11 FGD6 USP21	3.62e-04	260	81	5	15761153
Pubmed	Defining the membrane proteome of NK cells.	MTA2 ACAP1 GBF1 SYNE3 ERCC6L NUCB1 NAA10 CDC5L CCDC88B OPA1	3.80e-04	1168	81	10	19946888
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	CYLD AMPD2 CTNNA2 SPECC1L CDC5L ARHGEF11 CCDC177 OPA1 TRIM3	4.04e-04	963	81	9	28671696
Pubmed	Differentiation of pluripotent stem cells to muscle fiber to model Duchenne muscular dystrophy.	MESP2 MSGN1	4.11e-04	13	81	2	26237517
Pubmed	Transcriptional cofactor CA150 regulates RNA polymerase II elongation in a TATA-box-dependent manner.	POLR2A POLR2L	4.11e-04	13	81	2	10373521
Pubmed	MOF-associated complexes ensure stem cell identity and Xist repression.	KANSL2 KANSL1	4.11e-04	13	81	2	24842875
Pubmed	Architecture of RNA polymerase II and implications for the transcription mechanism.	POLR2A POLR2L	4.11e-04	13	81	2	10784442
Pubmed	Fgf4 maintains Hes7 levels critical for normal somite segmentation clock function.	MESP2 MSGN1	4.11e-04	13	81	2	33210601
Pubmed	TIP30 has an intrinsic kinase activity required for up-regulation of a subset of apoptotic genes.	POLR2A POLR2L	4.11e-04	13	81	2	10698937
Pubmed	The mouse rib-vertebrae mutation disrupts anterior-posterior somite patterning and genetically interacts with a Delta1 null allele.	MESP2 MESP1	4.11e-04	13	81	2	10906448
Pubmed	BRCA1 interaction with RNA polymerase II reveals a role for hRPB2 and hRPB10alpha in activated transcription.	POLR2A POLR2L	4.11e-04	13	81	2	10725406
Pubmed	FACT facilitates chromatin transcription by RNA polymerases I and III.	POLR2A POLR2L	4.11e-04	13	81	2	19214185
Pubmed	Specific binding of RNA polymerase II to the human immunodeficiency virus trans-activating region RNA is regulated by cellular cofactors and Tat.	POLR2A POLR2L	4.11e-04	13	81	2	7638159
Pubmed	Formal proof of the requirement of MESP1 and MESP2 in mesoderm specification and their transcriptional control via specific enhancers in mice.	MESP2 MESP1	4.11e-04	13	81	2	34679163
Pubmed	ZMYM3 regulates BRCA1 localization at damaged chromatin to promote DNA repair.	MTA2 KAT5 KANSL1 CDC5L	4.27e-04	150	81	4	28242625
Pubmed	Identification of novel inhibitors of human immunodeficiency virus type 1 replication by in silico screening targeting cyclin T1/Tat interaction.	POLR2A POLR2L	4.79e-04	14	81	2	23274668
Pubmed	Control of HIV latency by epigenetic and non-epigenetic mechanisms.	POLR2A POLR2L	4.79e-04	14	81	2	22211660
Pubmed	Regulatory functions of Cdk9 and of cyclin T1 in HIV tat transactivation pathway gene expression.	POLR2A POLR2L	4.79e-04	14	81	2	10536359
Pubmed	The ability of positive transcription elongation factor B to transactivate human immunodeficiency virus transcription depends on a functional kinase domain, cyclin T1, and Tat.	POLR2A POLR2L	4.79e-04	14	81	2	9696809
Pubmed	HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter.	POLR2A POLR2L	4.79e-04	14	81	2	12114499
Pubmed	Cyclin T1 domains involved in complex formation with Tat and TAR RNA are critical for tat-activation.	POLR2A POLR2L	4.79e-04	14	81	2	10329125
Pubmed	The human immunodeficiency virus Tat proteins specifically associate with TAK in vivo and require the carboxyl-terminal domain of RNA polymerase II for function.	POLR2A POLR2L	4.79e-04	14	81	2	8676484
Pubmed	Genetic rescue of segmentation defect in MesP2-deficient mice by MesP1 gene replacement.	MESP2 MESP1	4.79e-04	14	81	2	9739106
Pubmed	Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor.	POLR2A POLR2L	4.79e-04	14	81	2	7853496
Pubmed	Human and rodent transcription elongation factor P-TEFb: interactions with human immunodeficiency virus type 1 tat and carboxy-terminal domain substrate.	POLR2A POLR2L	4.79e-04	14	81	2	10364292
Pubmed	A high-throughput approach for measuring temporal changes in the interactome.	MTA2 USP34 AMPD2 GBF1 TBC1D4 MAN2B1 ARHGEF1 POLR2A ARIH2 NUCB1 NAA10	5.46e-04	1455	81	11	22863883
Pubmed	A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA.	POLR2A POLR2L	5.52e-04	15	81	2	9491887
Pubmed	HIV-1 Tat-associated RNA polymerase C-terminal domain kinase, CDK2, phosphorylates CDK7 and stimulates Tat-mediated transcription.	POLR2A POLR2L	5.52e-04	15	81	2	12049628
Pubmed	Cooperative interaction between HIV-1 regulatory proteins Tat and Vpr modulates transcription of the viral genome.	POLR2A POLR2L	5.52e-04	15	81	2	10931842
Pubmed	Interaction between Notch signalling and Lunatic fringe during somite boundary formation in the mouse.	MESP2 MESP1	5.52e-04	15	81	2	10330372
Interaction	DDX17 interactions	CYLD AMPD2 RC3H1 POLR2A ARIH2 GAS8 AATF CDC5L SMC5 TRIM3	7.05e-06	426	80	10	int:DDX17
Interaction	YJU2 interactions	KAT5 CLCN2 TRIM62 GAS8 CDC5L	9.87e-06	72	80	5	int:YJU2
Interaction	CSTPP1 interactions	PNMA5 GBF1 SPECC1L SMC5 OPA1	1.76e-05	81	80	5	int:CSTPP1
GeneFamily	Ubiquitin specific peptidases	CYLD USP34 USP42 USP21	2.00e-05	56	52	4	366
GeneFamily	Pleckstrin homology domain containing\|Rho guanine nucleotide exchange factors\|C2 domain containing	ARHGEF1 ARHGEF11 FGD6	9.04e-04	66	52	3	722
GeneFamily	Zinc fingers C2HC-type\|PHD finger proteins\|Lysine acetyltransferases	KAT5 ZFPM2	9.49e-04	16	52	2	66
GeneFamily	RNA polymerase subunits	POLR2A POLR2L	3.13e-03	29	52	2	726
GeneFamily	Basic helix-loop-helix proteins	MXD3 MESP2 MESP1	3.90e-03	110	52	3	420
GeneFamily	Ankyrin repeat domain containing	ACAP1 ASZ1 ANKFN1 GPANK1	5.13e-03	242	52	4	403
Coexpression	GSE5099_UNSTIM_VS_MCSF_TREATED_MONOCYTE_DAY7_DN	AMPD2 TBC1D4 MAN2B1 SNX32 POLR2A ARIH2 NUCB1	2.69e-06	200	80	7	M6585
ToppCell	COVID_non-vent-Lymphocytic-T_cell-CD4+_Naive_T_cell\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	CYLD ACAP1 FAM153B FAM153A TBC1D4 SFI1 RIC3	7.33e-08	197	81	7	836dd8110d5689f944ad1d301def38c32278b5b5
ToppCell	BAL-Mild-cDC_0\|Mild / Compartment, Disease Groups and Clusters	PNMA5 SYNE3 USP42 SNX32 LINC02693 CFAP210	5.34e-07	163	81	6	7047d3ba847930f42a6d5f71e18d49f3071c6409
ToppCell	10x5'-Liver-Lymphocytic_T_CD4-T_CD4/CD8\|Liver / Manually curated celltypes from each tissue	USP34 CDK17 BICDL1 ACAP1 KANSL1 SFI1	9.86e-07	181	81	6	f2315414e714ac86211546a935660c4be6e85f1b
ToppCell	10x3'2.3-week_14-16-Lymphocytic_T-T_NK-CD4_T_cell\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	CYLD BICDL1 ACAP1 TBC1D4 ARHGEF1 RIC3	1.12e-06	185	81	6	32f43ddc8a899827924834546db33928e353271b
ToppCell	10x3'2.3-week_14-16-Lymphocytic_T-T_NK\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	CYLD BICDL1 ACAP1 TBC1D4 ARHGEF1 RIC3	1.52e-06	195	81	6	146e482f660c0f234a3d15495ad9e7ed7b88fdc8
ToppCell	10x3'2.3-week_14-16-Lymphocytic_T\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	CYLD BICDL1 ACAP1 TBC1D4 ARHGEF1 RIC3	1.52e-06	195	81	6	efc71886b8521539dcba9d5c1a8304eec2dc6c42
ToppCell	healthy_donor-Lymphocytic-T_cell\|healthy_donor / Disease condition, Lineage, Cell class and subclass	CYLD BICDL1 ACAP1 FAM153B FAM153A TBC1D4	1.61e-06	197	81	6	63d0f06e150e7eb800ecb70e97b9d12a01c84e37
ToppCell	3'_v3-lymph-node_spleen-Lymphocytic_T_CD4-T_CD4/CD8\|lymph-node_spleen / Manually curated celltypes from each tissue	CYLD BICDL1 ACAP1 KANSL1 SFI1	1.52e-05	171	81	5	2e9a20f8980b78325c52065a9c14ab3656267c05
ToppCell	(1)_T_CD4_naive\|World / Spleen cell shreds - cell class (v1) and cell subclass (v1)	CYLD ACAP1 FAM153B FAM153A TBC1D4	2.39e-05	188	81	5	b8f67ac2faadd5b848955e43ab5d6cf5e49b3681
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	BCL9L BICDL1 ACAP1 FAM153A TBC1D4	2.45e-05	189	81	5	9ab77c6fcb573854da5922412f53d2168bda6b58
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c06-NR4A2\|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k)	CYLD BICDL1 ACAP1 TBC1D4 RIC3	2.45e-05	189	81	5	8130102c41b2978a8b83f765ce383f836a464795
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	BCL9L BICDL1 ACAP1 FAM153A TBC1D4	2.45e-05	189	81	5	5a9e2ca9a9ee2dc37ab9147a902115a9f1a80169
ToppCell	10x5'-lymph-node_spleen-Lymphocytic_T_CD4-T_CD4/CD8\|lymph-node_spleen / Manually curated celltypes from each tissue	CDK17 BICDL1 KANSL1 POLR2A SFI1	2.65e-05	192	81	5	47646d7e4990be85072987f92bf18d52f8da752e
ToppCell	PBMC-Severe-Lymphocyte-T/NK-CD4+_T-CD4+_T_activated-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CYLD ACAP1 TBC1D4 SFI1 RIC3	2.71e-05	193	81	5	2901d7a9672a8cf70c9f1c752685b45e4d79ac70
ToppCell	PBMC-Control-Lymphocyte-T/NK-CD8+_T-CD8+_T_naive\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	ACAP1 FAM153B FAM153A TBC1D4 RIC3	2.71e-05	193	81	5	d371403b51281a6e37652fa8dc1b2dd81d2ab371
ToppCell	COVID-19_Severe-Lymphoid_T/NK-CD4+_T_activated\|COVID-19_Severe / Disease group, lineage and cell class	CYLD ACAP1 TBC1D4 SFI1 RIC3	2.71e-05	193	81	5	beb862d38b88572836b0a797c8efef7a2492e0b9
ToppCell	PBMC-Control-Lymphocyte-T/NK-CD8+_T-CD8+_T_naive-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	ACAP1 FAM153B FAM153A TBC1D4 RIC3	2.71e-05	193	81	5	6436d3bfce02d137b76e5c4c8b2fe27974c57c99
ToppCell	PBMC-Severe-Lymphocyte-T/NK-CD4+_T-CD4+_T_activated\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CYLD ACAP1 TBC1D4 SFI1 RIC3	2.71e-05	193	81	5	f4310faa13fc8ce99a217e2d1c9cc733683797a1
ToppCell	PBMC-Control-Lymphocyte-T/NK-CD8+_T-CD8+_T_naive-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	ACAP1 FAM153B FAM153A TBC1D4 RIC3	2.71e-05	193	81	5	3cde93bbfc1ae6fb586ae6b7aaa6ed8b5eee28a4
ToppCell	PBMC-Control-Lymphocyte-T/NK-CD8+_T-CD8+_T_naive\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	ACAP1 FAM153B FAM153A TBC1D4 RIC3	2.71e-05	193	81	5	d755dc6de4fbd4d8f5d8a88aac497e7b9e8b89de
ToppCell	PBMC-Severe-Lymphocyte-T/NK-CD4+_T-CD4+_T_activated-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	CYLD ACAP1 TBC1D4 SFI1 RIC3	2.71e-05	193	81	5	f8af695457d2a0a911a5ac491742465864ebda37
ToppCell	PBMC-Severe-Lymphocyte-T/NK-CD4+_T-CD4+_T_activated\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	CYLD ACAP1 TBC1D4 SFI1 RIC3	2.71e-05	193	81	5	089aece40130034a89a5213be778f10b0787eeba
ToppCell	COVID-19_Severe-CD4+_T_naive\|World / disease group, cell group and cell class	CYLD BICDL1 ACAP1 TBC1D4 RIC3	2.92e-05	196	81	5	b47c89eca6053c309fd328251c4fa33a76d16889
ToppCell	COVID-19_Severe-Lymphoid_T/NK-CD4+_T_naive\|COVID-19_Severe / Disease group, lineage and cell class	CYLD ACAP1 FAM153A TBC1D4 RIC3	2.99e-05	197	81	5	07f74bdadfd28e1d55b3f4a3bf87d5dd65a2e9c5
ToppCell	PBMC-Severe-Lymphocyte-T/NK-CD4+_T-CD4+_T_naive\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CYLD ACAP1 FAM153A TBC1D4 RIC3	2.99e-05	197	81	5	9f0d91bb7aec4f2442259eca1ddf7905f8d40e9b
ToppCell	healthy_donor-Lymphocytic-T_cell-CD4+_Naive_T_cell\|healthy_donor / Disease condition, Lineage, Cell class and subclass	CYLD ACAP1 FAM153B FAM153A TBC1D4	2.99e-05	197	81	5	cf72160f03105876641fa6fdc7405e339eb084c7
ToppCell	PBMC-Severe-Lymphocyte-T/NK-CD4+_T-CD4+_T_naive-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CYLD ACAP1 FAM153A TBC1D4 RIC3	2.99e-05	197	81	5	258dfe69b5faeaee709422f873b144ca5e4a6452
ToppCell	T_cells-Treg_cells\|World / Immune cells in Kidney/Urine in Lupus Nephritis	BICDL1 FAM153A TBC1D4 SFI1 RIC3	2.99e-05	197	81	5	de5448fcdf4e433fc167496413abe5d0c8a5c6d8
ToppCell	PBMC-Severe-Lymphocyte-T/NK-CD4+_T-CD4+_T_naive\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	CYLD ACAP1 FAM153A TBC1D4 RIC3	2.99e-05	197	81	5	bf80e39cd68fd5bb85c8726d4f82648391de74ad
ToppCell	PBMC-Severe-Lymphocyte-T/NK-CD4+_T-CD4+_T_naive-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	CYLD ACAP1 FAM153A TBC1D4 RIC3	2.99e-05	197	81	5	296b27348ca7e9acf746f752cf810e4e5baea76c
ToppCell	COVID-19_Severe-CD4+_T_naive\|COVID-19_Severe / Disease condition and Cell class	CYLD FAM153B FAM153A TBC1D4 RIC3	2.99e-05	197	81	5	ac26672bd2cb3bc9a11206d8da203bafec3931f6
ToppCell	COVID_vent-Lymphocytic-T_cell-CD4+_Naive_T_cell\|COVID_vent / Disease condition, Lineage, Cell class and subclass	CYLD ACAP1 FAM153B FAM153A TBC1D4	3.14e-05	199	81	5	885bc902b6e2af0b61e452c4154160cd3f1cf98e
ToppCell	Control-Control-Lymphocyte-T/NK-CD4+_T_naive\|Control / Disease, condition lineage and cell class	CYLD ACAP1 FAM153A TBC1D4 RIC3	3.22e-05	200	81	5	59b446cd886767f19553aed779ab313685789f6f
ToppCell	COVID-19-COVID-19_Severe-Lymphocyte-T/NK-CD4+_T_naive\|COVID-19_Severe / Disease, condition lineage and cell class	CYLD ACAP1 FAM153A TBC1D4 RIC3	3.22e-05	200	81	5	1fb96090b5205e95ec21378bf4b88eec7257cf7e
ToppCell	TCGA-Bile_Duct-Primary_Tumor-Cholangiocarcinoma-Intrahepatic\|TCGA-Bile_Duct / Sample_Type by Project: Shred V9	VPS37C KANSL2 SLC4A1AP LAMC1 FGD6	3.22e-05	200	81	5	1fa8422fd820d21e285a7e7c4c6fbd8b7277d2af
ToppCell	COVID-19-COVID-19_Severe-Lymphocyte-T/NK-CD4+_T_activated\|COVID-19_Severe / Disease, condition lineage and cell class	CYLD ACAP1 TBC1D4 SFI1 RIC3	3.22e-05	200	81	5	deeed668b129e66156b5f6abe1a07a9bf842a14d
ToppCell	Striatum-Neuronal-Excitatory-eN3(Slc17a7_Gad1Gad2)-Drd1-Excitatory_Neuron.Gad1Gad2.Drd1-Otof-Sorcs1_(eccentric_SPN,_dSPN-like_markers)\|Striatum / BrainAtlas - Mouse McCarroll V32	PNMA5 KLK10 ANKFN1	8.61e-05	47	81	3	eef028d66c49406e71387e59bf7dddf5d5247472
ToppCell	Striatum-Neuronal-Excitatory-eN3(Slc17a7_Gad1Gad2)-Drd1-Excitatory_Neuron.Gad1Gad2.Drd1-Otof-Sorcs1_(eccentric_SPN,_dSPN-like_markers)-\|Striatum / BrainAtlas - Mouse McCarroll V32	PNMA5 KLK10 ANKFN1	8.61e-05	47	81	3	6420abf8a0094a1de6dea0670d5820b99edff78d
ToppCell	PBMC-Mild-Lymphocyte-T/NK-CD4+_T-Treg-Treg_2\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	PNMA5 TBC1D4 ASZ1 ZFPM2	1.42e-04	145	81	4	734d85ca7a2e5e040f433cadc5f9be1f25cf2e91
ToppCell	PBMC-Mild-Lymphocyte-T/NK-CD4+_T-Treg-Treg_2\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	PNMA5 TBC1D4 ASZ1 ZFPM2	1.42e-04	145	81	4	8ba09eb0fd27f25aa90a3ad75d67a9f79f3f4f43
ToppCell	Ciliated_cells-A-IPF_03\|World / lung cells shred on cell class, cell subclass, sample id	KCNV1 DNAI2 CFAP210 CTNNA2	1.46e-04	146	81	4	20f080318e9cbfd9b8b90a5e9f704d6d85b969ee
ToppCell	IIH-CD8-proli_CD4\|IIH / Condition, Cell_class and T cell subcluster	MXD3 MAN2B1 MESP1 TRIM3	1.46e-04	146	81	4	7fa6e35def3f7cffbee1e1c2f10b523bab678e14
ToppCell	control-Myeloid-Monocyte-derived_Macrophage\|Myeloid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	CDK17 FBXL18 TRIM62 VASH1	1.46e-04	146	81	4	69e9c1ec6eec1151290227902e75e77a4aecc8db
ToppCell	PND01-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal-Deuterosomal\|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	DNAI2 CCDC177 ANKFN1 ODAD3	1.66e-04	151	81	4	e335dad89e0a44cdd302b9653154ba5d1ee5fe1a
ToppCell	PND01-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal-Deuterosomal-Deuterosomal_mature\|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	DNAI2 CCDC177 ANKFN1 ODAD3	1.66e-04	151	81	4	633ed52dd3b4cf1e87432cf0a1ca187d7b204e83
ToppCell	Striatum-Neuronal-Excitatory-eN3(Slc17a7_Gad1Gad2)-Drd1-Excitatory_Neuron.Gad1Gad2.Drd1-Otof-Lmo2_(eccentric_SPN,_dSPN-like_markers)-\|Striatum / BrainAtlas - Mouse McCarroll V32	PNMA5 KLK10 ANKFN1	1.70e-04	59	81	3	dbb61f03be7d2c7fa7d32c743fcff2dc91ae0d75
ToppCell	Striatum-Neuronal-Excitatory-eN3(Slc17a7_Gad1Gad2)-Drd1-Excitatory_Neuron.Gad1Gad2.Drd1-Otof-Lmo2_(eccentric_SPN,_dSPN-like_markers)\|Striatum / BrainAtlas - Mouse McCarroll V32	PNMA5 KLK10 ANKFN1	1.70e-04	59	81	3	e6cbbe1a4961066cae8f8c03a838f37e60a5391a
ToppCell	BAL-Mild-Myeloid-cDC-cDC-cDC_0\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	PNMA5 SYNE3 USP42 SNX32	2.02e-04	159	81	4	2f6c60ddff2208a68146f9786143d9aefd528840
ToppCell	BAL-Mild-Myeloid-cDC-cDC-cDC_0\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	PNMA5 SYNE3 USP42 SNX32	2.02e-04	159	81	4	ded4e3626a62fb6334403b7213b467fb7e8131c3
ToppCell	E18.5-Immune-Immune_Myeloid-DC-cDC1-cDC1_mature\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MAN2B1 DENND4B AATF CCDC88B	2.17e-04	162	81	4	388670cf3acef17df971c0d8ae3ce14398945192
ToppCell	droplet-Kidney-KIDNEY-30m-Lymphocytic-CD45____NK_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ERCC6L APAF1 SMC5 ZXDB	2.17e-04	162	81	4	04a96442e0fcdb6a65b9e45044021677f9f53d38
ToppCell	droplet-Kidney-KIDNEY-30m-Lymphocytic-NK_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ERCC6L APAF1 SMC5 ZXDB	2.17e-04	162	81	4	7adb3e279526e1f21033c10af0a0058258f21842
ToppCell	E18.5-Immune-Immune_Myeloid-DC-cDC1\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MAN2B1 DENND4B AATF CCDC88B	2.17e-04	162	81	4	9333d923225df7bfdf6b3a4c32816751315aec50
ToppCell	E18.5-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_ILC-NK-NK-NK_G2M\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ACAP1 CLCN2 ARHGEF1 DENND4B	2.33e-04	165	81	4	ec16a4979b3f203c9f66ed387a7a17bf3a1d3f86
ToppCell	Control-Epithelial-Mesothelial\|Control / Disease state, Lineage and Cell class	FAM153B KLK10 FAM153A ZFPM2	2.38e-04	166	81	4	1ed3788257e14f097862b999f020bfe2a57de52b
ToppCell	systemic_lupus_erythematosus-flare-Lymphocytic_T-T4_reg-male\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	CYLD ACAP1 TBC1D4 ARHGEF1	2.73e-04	172	81	4	9497948bbe53fb88c6ff6b347f743d456da587e5
ToppCell	367C-Fibroblasts-Fibroblast-J_(Lipofibroblast)\|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)	BICDL1 FAM153B KLK10 DNAI2	2.79e-04	173	81	4	3d7c281a1a9f183a5a861d1a9c7b50d216535893
ToppCell	PND07-Immune-Immune_Myeloid-DC-cDC1-cDC1_prolif\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	VPS37C TBC1D4 FBXL18 CCDC51	2.79e-04	173	81	4	28c98a9a54aa2cfa67464db4f628c9357ad185b9
ToppCell	367C-Fibroblasts-Fibroblast-J_(Lipofibroblast)-\|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)	BICDL1 FAM153B KLK10 DNAI2	2.79e-04	173	81	4	3aa90578371039f81b7c6fa873ec70f8f2bc7dfa
ToppCell	PND07-28-samps-Epithelial-Epithelial-non_alveolar-Ciliated_cell_of_lung_parenchyma\|PND07-28-samps / Age Group, Lineage, Cell class and subclass	DNAI2 ULK4 ANKFN1 ODAD3	2.85e-04	174	81	4	f41d05a3703d7092bd3c4a97c15ae13069aaa4ad
ToppCell	PND07-28-samps-Epithelial-Epithelial-non_alveolar\|PND07-28-samps / Age Group, Lineage, Cell class and subclass	DNAI2 ULK4 ANKFN1 ODAD3	2.91e-04	175	81	4	c01a15b2084da4a18f8ff3623f44eb9dfe499f10
ToppCell	LPS-antiTNF-Lymphocytic_NKT-T_cells\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CYLD BICDL1 ACAP1 ARHGEF1	2.98e-04	176	81	4	ea27e18407b8a13e8212830da859efeb8f158690
ToppCell	3'-GW_trimst-2-SmallIntestine-Hematopoietic-T_cells-Treg\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	PNMA5 ACAP1 TBC1D4 DNAI2	2.98e-04	176	81	4	88247142c6482f3b4fa845d64e6189c690a5ee52
ToppCell	LPS-antiTNF-Lymphocytic_NKT-T_cells-T-cells\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CYLD BICDL1 ACAP1 ARHGEF1	2.98e-04	176	81	4	bfbab3c5b738b3b0b1540f2059d0245fbd8c0031
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell\|Severe-critical_progression_d12-22 / Compartment, severity and other cell annotations on 10x 3' data (130k)	KCNV1 FAM153A TBC1D4 SFI1	3.04e-04	177	81	4	64b8f665fdaf975558af2ad7d9b54d206de8350c
ToppCell	Control-Lymphocytic_NKT-T_cells-T-cells\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CYLD BICDL1 ACAP1 ARHGEF1	3.11e-04	178	81	4	910f8bea19d335455aba24e6a07b4834b709db5d
ToppCell	Fetal_29-31_weeks-Epithelial-ciliated_cell-D062\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	DNAI2 CFAP210 ANKFN1 ODAD3	3.11e-04	178	81	4	de5d50d7ca9ee9eb62f50c88a0c6d47f0694b2e6
ToppCell	Control-Lymphocytic_NKT-T_cells\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CYLD BICDL1 ACAP1 ARHGEF1	3.17e-04	179	81	4	d892d9496f1c33e23312092591eb2e968e736f7d
ToppCell	Adult-Epithelial-ciliated_cell-D122\|Adult / Lineage, Cell type, age group and donor	DNAI2 CFAP210 ANKFN1 ODAD3	3.38e-04	182	81	4	7ded554a4b441e6496db673ba206c0d76ccad7d9
ToppCell	5'-Airway_Nasal-Immune_Myeloid-Myeloid_macrophage-lung_macrophage\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	BCL9L AMPD2 FGD6 GASK1B	3.38e-04	182	81	4	4a85429d365c4b2d73fc921f261b4b7635ac40bd
ToppCell	5'-Airway_Nasal-Immune_Myeloid-Myeloid_macrophage-lung_macrophage-Interstitial_macrophage_perivascular\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	BCL9L AMPD2 FGD6 GASK1B	3.38e-04	182	81	4	53213af34af3337f5edc734d3b7b79e4349eac0d
ToppCell	PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c06-NR4A2\|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k)	CYLD BICDL1 ACAP1 TBC1D4	3.38e-04	182	81	4	9ba85f621a846531a2a7861e9df695d288c9e149
ToppCell	5'-Airway_Nasal-Immune_Myeloid-Myeloid_macrophage-lung_macrophage-Interstitial_macrophage_perivascular-Interstitial_macrophage_perivascular_L.1.2.1.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	BCL9L AMPD2 FGD6 GASK1B	3.38e-04	182	81	4	7909089ed6325c44edd6f9b7e8b1d542398222ea
ToppCell	5'-GW_trimst-2-LargeIntestine-Mesenchymal-mesothelial_cell-Mesothelium\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	BICDL1 FAM153B KLK10 RIC3	3.45e-04	183	81	4	9d5a363fbe6f0a1668c9d584df65ee1c283349c7
ToppCell	5'-GW_trimst-2-LargeIntestine-Mesenchymal-mesothelial_cell\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	BICDL1 FAM153B KLK10 RIC3	3.45e-04	183	81	4	c5caac6ed6c8d67f5c336281d9fd903976509445
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c01-LEF1\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	BICDL1 FAM153A TBC1D4 RIC3	3.52e-04	184	81	4	5350b58aa9979631228835d11eb45ddf81d08bff
ToppCell	Children_(3_yrs)-Epithelial-ciliated_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	DNAI2 CFAP210 ANKFN1 ODAD3	3.52e-04	184	81	4	5daff849625f2f41d56615569c0ed59cd733b34c
ToppCell	Adult-Epithelial-ciliated_cell-D175\|Adult / Lineage, Cell type, age group and donor	DNAI2 CFAP210 ANKFN1 ODAD3	3.60e-04	185	81	4	30f4980dee6cd5959655f8d74049f3bfb5312611
ToppCell	Fetal_29-31_weeks-Epithelial-ciliated_cell-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	DNAI2 CFAP210 ANKFN1 ODAD3	3.60e-04	185	81	4	3e39a3cb534dfe2301930f3e2f7e8cefb522c158
ToppCell	367C-Lymphocytic-CD4_T-cell-CD4+_Effector_T_cell-1\|367C / Donor, Lineage, Cell class and subclass (all cells)	BICDL1 ACAP1 ARHGEF1 RIC3	3.67e-04	186	81	4	d4be02813d590aa7ffe0d1553a27d257b9ab77fe
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	KCNV1 FAM153B FAM153A ZFPM2	3.82e-04	188	81	4	50c1b1d690f0e9443082f2adf4f1b8e9ce4cd337
ToppCell	3'_v3-Lung-Lymphocytic_T_CD4-Tregs\|Lung / Manually curated celltypes from each tissue	BICDL1 ACAP1 TBC1D4 RIC3	3.82e-04	188	81	4	604f340052807bd902915eca942a97ccc36b42e0
ToppCell	control-immature_Neutrophil\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	RHOB ERCC6L ARHGEF11 GASK1B	3.90e-04	189	81	4	bdfd120900ba58d5e54765f7b576e1f8cc2401bf
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD8_c01-LEF1\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	BCL9L FAM153A TBC1D4 SFI1	3.90e-04	189	81	4	e9df7ecd36bee1fedce23bb188c68a94fa60462c
ToppCell	COPD-Epithelial-Ciliated\|Epithelial / Disease state, Lineage and Cell class	DNAI2 ULK4 CFAP210 ANKFN1	3.90e-04	189	81	4	3e77883db34722b9ce0a03ea74caefc92dc7feff
ToppCell	tumor_Lung-Fibroblasts-Mesothelial_cells\|Fibroblasts / Location, Cell class and cell subclass	BICDL1 FAM153B KLK10 FAM153A	3.98e-04	190	81	4	d82ab67735c1f365d4b0e02b5fa91c64cdc234da
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	BICDL1 FAM153A TBC1D4 SFI1	4.06e-04	191	81	4	d9a6f61fcda4f5352488f7f55cb9b57aeacc717f
ToppCell	LA-05._Cytoplasmic_Cardiomyocyte_I\|World / Chamber and Cluster_Paper	BICDL1 FAM153B FAM153A POLR2L	4.06e-04	191	81	4	d825e55278dce666c332cc060d1255659e07e568
ToppCell	COVID-19_Moderate-CD4+_Tcm\|World / disease group, cell group and cell class	CYLD BICDL1 ACAP1 RIC3	4.14e-04	192	81	4	5f94310f1470487816fce697ffcdc2627fc66878
ToppCell	COVID-19_Moderate-CD4+_T_activated\|COVID-19_Moderate / disease group, cell group and cell class	CYLD BICDL1 ACAP1 TBC1D4	4.14e-04	192	81	4	7a81652406332afd03a9b3b529e9b5e6c0b54c28
ToppCell	COVID-19_Severe-CD4+_Tcm\|World / disease group, cell group and cell class	CYLD BICDL1 ACAP1 TBC1D4	4.14e-04	192	81	4	3352f13a6e706991dcf3ec173587bb6aba36a385
ToppCell	COVID-19_Moderate-CD4+_T_activated\|World / disease group, cell group and cell class	CYLD BICDL1 ACAP1 TBC1D4	4.22e-04	193	81	4	c2a2a2c14a7085690262db5c2a70e38db67dee18
ToppCell	Control-Epithelial-Ciliated\|Epithelial / Disease state, Lineage and Cell class	DNAI2 ULK4 CFAP210 ANKFN1	4.22e-04	193	81	4	0e37d454f3735edd936ee9a5f5f516ac3aad400e
ToppCell	Control-CD8+_T_naive\|Control / Disease condition and Cell class	FAM153B FAM153A TBC1D4 RIC3	4.22e-04	193	81	4	627d345baf1940218c61907305705298e473dbab
ToppCell	IPF-Epithelial-Ciliated\|Epithelial / Disease state, Lineage and Cell class	DNAI2 ULK4 CFAP210 ANKFN1	4.22e-04	193	81	4	ad58f5080e0ba65c845056ea6b79037b636e9c64
ToppCell	PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c03-ITGA4\|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k)	CYLD BICDL1 TBC1D4 RIC3	4.22e-04	193	81	4	194b49c152e3e3f599068ec88a7f0af6427b743a
ToppCell	COVID-19_Severe-CD4+_Tcm\|COVID-19_Severe / disease group, cell group and cell class	CYLD BICDL1 ACAP1 TBC1D4	4.22e-04	193	81	4	45fe14c10b71459047608c8931d83c9c533f97f9
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell\|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k)	ACAP1 FAM153A TBC1D4 RIC3	4.22e-04	193	81	4	192432ce2f8f95f8b8fa3812d311d35ee2b89f86
ToppCell	PBMC-Control-Lymphocyte-T/NK-CD4+_T-CD4+_T_naive-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	ACAP1 FAM153A TBC1D4 RIC3	4.30e-04	194	81	4	2e2019a7bf57f257f0ff9b24eacff59dbb952ebb
ToppCell	PBMC-Mild-Lymphocyte-T/NK-CD4+_T-CD4+_Tcm-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CYLD BICDL1 ACAP1 TBC1D4	4.30e-04	194	81	4	929b97eb0a4a88cd566f832d4959b8b8a34c46b4
Computational	Genes in the cancer module 67.	MXD3 TRIM62 GAS8 POLR2L ULK4 ZMYM6 ZFPM2	3.91e-05	227	45	7	MODULE_67
Drug	Moxisylyte hydrochoride [964-52-3]; Down 200; 12.6uM; MCF7; HT_HG-U133A	MXD3 TBC1D4 KAT5 ARIH2 NUCB1 SMC5 OPA1 USP21	5.73e-07	200	81	8	7015_DN
Drug	retinoic acid; Down 200; 1uM; MCF7; HT_HG-U133A_EA	MTA2 CYLD MXD3 VASH1 SCAPER CDC5L TRIM3	5.58e-06	192	81	7	849_DN
Drug	Trazodone hydrochloride [25332-39-2]; Up 200; 9.8uM; MCF7; HT_HG-U133A	GBF1 CLCN2 TRIM62 VASH1 SCAPER SFI1 ARHGEF11	5.97e-06	194	81	7	7410_UP
Drug	pioglitazone HCl; Up 200; 10uM; MCF7; HT_HG-U133A	CYLD CLCN2 CTDP1 SFI1 CDC5L ARHGEF11 TRIM3	5.97e-06	194	81	7	7523_UP
Drug	Bufexamac [2438-72-4]; Down 200; 18uM; HL60; HT_HG-U133A	MTA2 MXD3 ACAP1 FBXL18 SLC22A14 ARIH2 ARHGEF11	6.39e-06	196	81	7	2382_DN
Drug	Triflupromazine hydrochloride [1098-60-8]; Down 200; 10.2uM; MCF7; HT_HG-U133A	CYLD AMPD2 ARIH2 APAF1 SFI1 ARHGEF11 TRIM3	6.39e-06	196	81	7	1691_DN
Drug	Flunarizine dihydrochloride [30484-77-6]; Down 200; 8.4uM; HL60; HT_HG-U133A	MTA2 MXD3 USP34 TBC1D4 SLC22A14 ARIH2 ARHGEF11	6.83e-06	198	81	7	2381_DN
Drug	ICI 182,780; Down 200; 0.01uM; PC3; HT_HG-U133A	KLK10 GBF1 TRIM62 ARIH2 APAF1 CTDP1 CDC5L	6.83e-06	198	81	7	1238_DN
Drug	LY 294002; Up 200; 10uM; MCF7; HT_HG-U133A	CYLD MXD3 APAF1 SCAPER SFI1 RIC3	5.85e-05	189	81	6	5587_UP
Drug	Captopril [62571-86-2]; Up 200; 17.2uM; HL60; HG-U133A	VPS37C GBF1 TBC1D4 POLR2A SMC5 OPA1	6.57e-05	193	81	6	1988_UP
Drug	Metoclopramide monohydrochloride [7232-21-5]; Down 200; 11.8uM; PC3; HT_HG-U133A	CYLD MXD3 FBXL18 CTDP1 ARHGEF11 TRIM3	6.57e-05	193	81	6	4285_DN
Drug	Methylprednisolone, 6-alpha [83-43-2]; Down 200; 10.6uM; PC3; HT_HG-U133A	CYLD KAT5 FBXL18 APAF1 CTDP1 POLR2L	6.76e-05	194	81	6	7137_DN
Drug	2-propylpentanoic acid; Down 200; 1000uM; PC3; HT_HG-U133A	VPS37C KAT5 POLR2A NUCB1 CDC5L USP21	6.76e-05	194	81	6	1209_DN
Drug	2-propylpentanoic acid; Up 200; 500uM; MCF7; HT_HG-U133A	GBF1 TBC1D4 FBXL18 SLC22A14 SCAPER SFI1	6.96e-05	195	81	6	6999_UP
Drug	Metolazone [17560-51-9]; Up 200; 11uM; MCF7; HT_HG-U133A	CYLD CLCN2 FBXL18 ARHGEF1 SCAPER ARHGEF11	6.96e-05	195	81	6	5392_UP
Drug	Solasodine [126-17-0]; Down 200; 9.6uM; MCF7; HT_HG-U133A	MTA2 SLC12A6 USP34 APAF1 CTDP1 SCAPER	7.16e-05	196	81	6	3830_DN
Drug	Clofilium tosylate [92953-10-1]; Down 200; 7.8uM; MCF7; HT_HG-U133A	AMPD2 FBXL18 ARIH2 GAS8 SCAPER POLR2L	7.16e-05	196	81	6	3187_DN
Drug	Pipemidic acid [51940-44-4]; Down 200; 13.2uM; HL60; HT_HG-U133A	MXD3 USP34 CDK17 ACAP1 ARHGEF1 CTDP1	7.16e-05	196	81	6	3093_DN
Drug	0225151-0000 [351320-15-5]; Down 200; 10uM; PC3; HT_HG-U133A	CYLD CSRNP3 SCAPER CDC5L TRIM3 RIC3	7.36e-05	197	81	6	6389_DN
Drug	Lincomycin hydrochloride [859-18-7]; Up 200; 9uM; MCF7; HT_HG-U133A	CLCN2 SLC22A14 ARIH2 APAF1 VASH1 SFI1	7.36e-05	197	81	6	7411_UP
Drug	Epirizole [18694-40-1]; Down 200; 17uM; PC3; HT_HG-U133A	SLC12A6 MXD3 GBF1 TBC1D4 SCAPER SPECC1L	7.36e-05	197	81	6	1803_DN
Drug	Isradipine [75695-93-1]; Up 200; 10.8uM; MCF7; HT_HG-U133A	CYLD SLC12A6 CLCN2 CTDP1 DNAI2 CTNNA2	7.36e-05	197	81	6	5447_UP
Drug	rottlerin; Down 200; 10uM; MCF7; HT_HG-U133A_EA	TRIM62 ARIH2 VASH1 CTDP1 ARHGEF11 TRIM3	7.57e-05	198	81	6	914_DN
Drug	Amodiaquin dihydrochloride dihydrate [6398-98-7]; Down 200; 8.6uM; MCF7; HT_HG-U133A	AMPD2 KAT5 NUCB1 CDC5L ARHGEF11 TRIM3	7.57e-05	198	81	6	6224_DN
Drug	Sulfanilamide [63-74-1]; Down 200; 23.2uM; MCF7; HT_HG-U133A	CDK17 CLCN2 LAMC1 CDC5L SMC5 ARHGEF11	7.57e-05	198	81	6	3449_DN
Drug	Estradiol-17 beta [50-28-2]; Down 200; 14.6uM; HL60; HT_HG-U133A	AMPD2 ACAP1 ARHGEF1 NUCB1 SCAPER ARHGEF11	7.57e-05	198	81	6	1299_DN
Drug	Riluzole hydrochloride; Down 200; 14.8uM; PC3; HT_HG-U133A	CDK17 SLC22A14 ARHGEF1 APAF1 SCAPER SFI1	7.57e-05	198	81	6	3666_DN
Drug	clozapine; Down 200; 10uM; MCF7; HT_HG-U133A_EA	MXD3 CDK17 ARIH2 APAF1 CTDP1 TRIM3	7.57e-05	198	81	6	1009_DN
Drug	Nafronyl oxalate [3200-06-4]; Up 200; 8.4uM; MCF7; HT_HG-U133A	CYLD SLC12A6 USP34 DNAI2 SFI1 RIC3	7.57e-05	198	81	6	2622_UP
Drug	Pepstatin A [26305-03-3]; Up 200; 5.8uM; MCF7; HT_HG-U133A	SLC12A6 APAF1 SCAPER SFI1 SMC5 ZMYM6	7.78e-05	199	81	6	3264_UP
Drug	Ungerine nitrate; Down 200; 10.2uM; MCF7; HT_HG-U133A	MXD3 AMPD2 MAN2B1 FBXL18 TRIM62 SFI1	7.78e-05	199	81	6	7173_DN
Drug	Tiletamine hydrochloride; Down 200; 15.4uM; PC3; HT_HG-U133A	USP34 TBC1D4 TRIM62 SCAPER POLR2L FGD6	7.78e-05	199	81	6	7311_DN
Drug	Pargyline hydrochloride [306-07-0]; Up 200; 20.4uM; MCF7; HT_HG-U133A	BICDL1 FBXL18 SLC22A14 CTDP1 SCAPER FGD6	7.78e-05	199	81	6	7016_UP
Drug	rosiglitazone; Down 200; 10uM; MCF7; HT_HG-U133A	CLCN2 ARIH2 SCAPER SFI1 ARHGEF11 TRIM3	7.78e-05	199	81	6	6950_DN
Drug	Disopyramide [3737-09-5]; Up 200; 11.8uM; MCF7; HT_HG-U133A	USP34 CLCN2 POLR2A TRIM62 SCAPER SFI1	7.78e-05	199	81	6	7439_UP
Drug	SB 203580; Up 200; 1uM; MCF7; HT_HG-U133A	TBC1D4 KAT5 ARIH2 APAF1 VASH1 TRIM3	8.00e-05	200	81	6	6899_UP
Disease	Primary ciliary dyskinesia	GAS8 DNAI2 ODAD3	1.15e-04	36	77	3	cv:C0008780
Disease	Primary Ciliary Dyskinesia	GAS8 DNAI2 ODAD3	2.55e-04	47	77	3	C4551720
Disease	macrophage inflammatory protein 1b measurement	ARIH2 AATF IP6K1 CCDC51	4.50e-04	136	77	4	EFO_0008219
Disease	advanced glycosylation end product-specific receptor, soluble measurement	KANSL1 ZFPM2	5.15e-04	13	77	2	EFO_0020131
Disease	Kartagener syndrome (implicated_via_orthology)	DNAI2 ODAD3	5.99e-04	14	77	2	DOID:0050144 (implicated_via_orthology)
Disease	diffuse idiopathic skeletal hyperostosis	CDC5L ANKFN1	6.90e-04	15	77	2	EFO_0007236
Disease	primary ciliary dyskinesia (implicated_via_orthology)	DNAI2 ODAD3	1.12e-03	19	77	2	DOID:9562 (implicated_via_orthology)
Disease	leprosy	CYLD KANSL1 CCDC88B	2.51e-03	103	77	3	EFO_0001054

Protein segments in the cluster

Peptide	Gene	Start	Entry
EEAKDRLRILMLRKH	APAF1	221	O14727
RLHRNRKLVLMVDLD	CTDP1	176	Q9Y5B0
HSLFLDRLMKRRQES	ARHGEF1	471	Q92888
KQMERESREHLRLGL	CDC5L	466	Q99459
LVRHRDLKANMRALE	CCDC88B	1096	A6NC98
LNRLKDMELAHRELL	ARHGEF11	1436	O15085
HDMEREIKTLHRRLR	SPECC1L	726	Q69YQ0
SAREKRDMEQRHVLL	ACAP1	231	Q15027
MHIAEQRRRTLLKDF	ARIH2	476	O95376
LRFIKRAMKRHLEEI	AMPD2	431	Q01433
REKILEARHREMRLK	DNAI2	506	Q9GZS0
KMLSDRKRELEHRLS	BICDL1	256	Q6ZP65
MTDLLKERDITLRHL	ASZ1	291	Q8WWH4
KERDITLRHLLTMRE	ASZ1	296	Q8WWH4
LDELHRRRKEIMAQL	RC3H1	751	Q5TC82
LRKALTHLEMRRAAR	MTA2	616	O94776
EREKLRMRTLADALH	MSGN1	131	A6NI15
LSLLRRARMHIQKLE	MXD3	96	Q9BW11
RSLEAEDKMTHRILR	GPANK1	96	O95872
LRLRDHLDRFSILMT	LINC02693	81	A8MQB3
KLRMRTLARALHELR	MESP2	91	Q0VG99
ILAKMSELVHRRLRH	ZFPM2	516	Q8WW38
VDGHERAMLKRLLRI	KAT5	481	Q92993
LHREMLREHLREEKL	CSRNP3	116	Q8WYN3
LLRALRMLKLGRHST	KCNV1	316	Q6PIU1
LTQMADELRRHLELK	NAA10	151	P41227
EMKRQLRRLRELHLY	FAM153A	11	Q9UHL3
MRLRDHSSERSEVLK	KANSL1	786	Q7Z3B3
RIHRRISMEDLNKRL	CDK17	131	Q00537
RLLHQLREITRVMKE	RIC3	186	Q7Z5B4
MLKEHERRRYLESLG	NUCB1	181	Q02818
LAALRHEIELRMRKN	OPA1	356	O60313
LSKDDIRRMRLLADS	GASK1B	216	Q6UWH4
LRRQLRKAVMDHISD	CTNNA2	376	P26232
EELLRHQLLEKRSMG	BCL9L	676	Q86UU0
DGSLELMVHRRLLKD	MAN2B1	806	O00754
KLASSMGKEELRHRR	DENND4B	1461	O75064
DRRSEMRLKHLDMVL	IP6K1	351	Q92551
MRLSELLRKSAEHTL	GBF1	171	Q92538
EALLHRQLKERRMLA	KANSL2	271	Q9H9L4
MTLLAEEARKLAERH	LAMC1	1176	P11047
ERDRKIAALMLARHQ	CCDC177	336	Q9NQR7
LKMSLEDLHSLDSRR	CYLD	916	Q9NQC7
MLLRRLRAVHTKQDD	SLC22A14	36	Q9Y267
LRHMRLSKTERDREA	SLC12A6	1001	Q9UHW9
LLDQRRRMMEEKLLH	SCAPER	586	Q9BY12
DIEMKRQLRRLRELH	FAM153B	86	P0C7A2
MDLLKRLRDEGHQTL	ERCC6L	466	Q2NKX8
LRGAERQKLMRADLH	SFI1	631	A8K8P3
LRSDEHVRTELARMK	RHOB	121	P62745
MRDRDLLHNSLLQRK	SYNE3	526	Q6ZMZ3
ATLEHRMLQEEKRLR	CCDC51	151	Q96ER9
ERMERKTHREHLLLQ	ODAD3	316	A5D8V7
SDMLKHCKRLRDLRL	FBXL18	581	Q96ME1
EKLRMRTLARALHEL	MESP1	91	Q9BRJ9
IDHILMDKERLLRRT	AATF	396	Q9NY61
MEASLTRRLLFKDRH	ANKFN1	1	Q8N957
AETHRLMEKRRERIH	CFAP210	316	Q0VFZ6
LMEKRRERIHNFLSE	CFAP210	321	Q0VFZ6
RLALHRTKGRMLALV	CLCN2	601	P51788
MEALRRAHEVALRLL	C15orf61	1	A6NNL5
VRSTDMIRLKHLLAR	PNMA5	281	Q96PV4
DDMLLSDKLVLRRLR	TIGD2	496	Q4W5G0
LLRHKRKHDDDRRFM	ZXDB	471	P98169
KHLRMESRDDRCRLF	USP42	1296	Q9H9J4
LKLLMERLHLEINRR	USP21	306	Q9UK80
LLRVELDRKHMTDRK	POLR2A	1211	P24928
LNRDLLKELEERMLH	FGD6	931	Q6ZV73
RRMLLAHVDLIEKLL	POLR2L	46	P62875
RAKIRCDMEDIHTLL	TBC1D4	901	O60343
GRMLKRLFELRHEIE	ZMYM6	1076	O95789
RGLLMLKTHLEAFRR	USP34	1166	Q70CQ2
LRADRVMRAHKCLAD	SNX32	226	Q86XE0
RKRHLDLIEMLEAKR	SMC5	256	Q8IY18
RKELERHARDMRLKI	VASH1	291	Q7L8A9
MLSHLRRVRVEKLQE	VPS37C	141	A5D8V6
HRLLRERQKAMLEEL	TRIM62	186	Q9BVG3
RERDMLRWKLFHAEL	TEX13B	141	Q9BXU2
EVLLVRKHMRERLAA	TRIM3	266	O75382
RILRRMITSNEKHLE	ULK4	1221	Q96C45
HRIQESVLRKDMRAL	GAS8	131	O95995
RRTDEHDLMLLKLAR	KLK10	131	O43240
RISKLHRLRMADILS	SLC4A1AP	46	Q9BWU0